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ABSTRACT
The Japanese Guideline for the Diagnosis and Treatment of Allergic Diseases 2013 (JAGL 2013) describes
childhood asthma after the Japanese Pediatric Guideline for the Treatment and Management of Asthma 2012
(JPGL 2012) by the Japanese Society of Pediatric Allergy and Clinical Immunology. JAGL 2013 provides infor-
mation on diagnosis by age group from infancy to puberty (0-15 years of age), treatment for acute exacerba-
tions, long-term management by anti-inflammatory drugs, daily life guidance, and patient education to allow
non-specialist physicians to refer to this guideline for routine medical treatment. JAGL differs from the Global
Initiative for Asthma Guideline (GINA) in that JAGL emphasizes early diagnosis and intervention at <2 years
and 2-5 years of age. A management method, including step-up or step-down of long-term management drugs
based on the status of asthma control levels, as in JAGL, is easy to understand, and thus the Guideline is suit-
able as a frame of reference for routine medical treatment. JAGL has also introduced treatment and manage-
ment using a control test on children, recommending that the physician aim at complete control by avoiding ex-
acerbation factors and by appropriate use of anti-inflammatory drugs.
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1. Definition and Pathophysiology of Child-
hood Asthma (Fig. 1)
Childhood asthma (0-15 years old) causes repeated
dyspnea accompanied by paroxysmal whistling
wheezing. The dyspnea is spontaneously or therapeu-
tically remitted or cured and rarely lethal. Like adult
asthma, childhood asthma is characterized by
chronic airway inflammation1,2 and airway remodel-
ing.3-7
Chronic airway inflammation is caused by the acti-
vation of eosinophils, mast cells and lymphocytes,
and by airway mucosal damage. The view that
asthma is a condition of chronic inflammation has im-
portant implications for asthma treatment and man-
agement; it is fundamental to the understanding of
the need for anti-inflammatory drugs for basic treat-
ment of persistent asthma. Remodeling, which may
influence the prognosis of asthma, is still unknown in
many aspects, such as its causes, onset time, and ef-
fects of anti-inflammatory treatment. Airway hyper-
responsiveness, which is characteristic of asthma, is
intensified by airway epithelial damage caused, in
turn, by airway inflammation. Airway hyper-
responsiveness can be assessed by patient’s reactions
to inhaled histamine, acetylcholine, etc. Exercise-
induced asthma (EIA) is also considered to be a phe-
nomenon associated with airway hyper-respons-
iveness．
2. Diagnosis and Differential Diagnosis of
Childhood Asthma
The typical symptom of asthma exacerbation is dysp-
nea accompanied by whistlingwheezing. Expiratory
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Fig.　1　Pathophysiology of bronchial asthma.
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Table　1　References for asthma diagnosis
1. Respiratory functions: spirogram, fl ow volume curve, peak fl ow (PER) rate, and reactivity and reversibility for β2 stimulants
2. Airway hyper-responsiveness test: acetylcholine and histamine thresholds and exercise stress test
3. Data indicating airway infl ammation: eosinophils, mast cells (basophils) in rhinorrhea and sputum, and concentration of nitric 
oxide (FeNO) in exhaled breath
4. IgE: total serum IgE level, specifi c IgE antibody, immediate skin response, and antigen inhalation test
5. Family and patients’ past histories of allergic diseases
Table　2　Differential diagnosis
Anomalies
Chest vascular malformation
Congenital heart diseases
Anomalies of airway
Laryngomalacia
Bronchomalacia
Tracheomalacia
Immotile cilia syndrome
Others
Hypersensitive pneumonitis
Bronchial foreign bodies
Psychogenic cough
Vocal cord dysfunction
Compression of airway
Pulmonary edema
Allergic bronchopulmonary 
aspergillosis
Cystic fi brosis
Sarcoidosis
Pulmonary embolism
Infection
Nasopharyngitis, sinusitis
Croop (acute laryngitis)
Bronchitis
Bronchiolitis
Pneumonia
Bronchiectasis
Pulmonary tuberculosis
dyspnea occurs mainly during an asthma exacerba-
tion. As symptoms progress, however, inspiratory
dyspnea may coexist. If such symptoms are repeated,
it is reasonable to diagnose symptomatic asthma. But
some patients present with misleading symptoms. Ta-
ble 1 summarizes the physiological and immunologi-
cal examinations and allergy tests, which may aid in
enhancing the accuracy of diagnosis.
2.1. Differential Diagnosis
Table 2 shows diseases that figure in differential diag-
nosis of wheezing in children. Children with wheez-
ing symptoms, particularly those with acute wheezing
must be differentially diagnosed. In infants, an accu-
mulation of secretion in the lower respiratory tract,
resulting from bronchitis, pneumonia, and others
may cause repeated wheezing; a differential diagnosis
is thus called for. Recurrent wheezing is easily diag-
nosed in older children with underlying diseases,
such as history of respiratory disorder and congenital
heart disease during infancy. However, caution
should be taken in the case of airway stenosis caused
by a vascular ring, for instance, and of wheezing re-
sulting from gastro-esophageal reflux disease.
2.2. Atopic Asthma and Non-Atopic Asthma
There are two types of childhood asthma: atopic
asthma and non-atopic asthma. Most of childhood
asthma cases are atopic, in which many patients ex-
hibit elevated specific IgE levels for house dust mites.
2.3. Asthma Phenotype
Recently, different asthma phenotypes in infantile pe-
riod came to be discussed. Martinez et al. classified
wheezing infants into three subtypes: transient early
wheezers, non-atopic wheezers and IgE-associated
wheezers8 (Fig. 2). Brand et al., in contrast, classified
wheezes among infants into two subtypes: multi-
Childhood Asthma
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Fig.　2　Asthma phenotypes in infancy.
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Table　3　Asthma prevalence rate in Japan
Surveillance 
area
Age
(years old)
Surveillance 
method
Surveillance year
1982 1992 1994 2002 2003 2005 2008 2012
Western area 
of Japan 6-12 ATS-DLD 3.20% 4.60% 6.50% 4.70%
Fukuoka
Prefecture of 
Japan
6-7
ISAAC
17.3% 18.2%
13-14 13.4% 13.0%
All Japan
0-4
Prevalence 
rate trend-
surveillance
13.6%
5-9 12.7%
10-14 9.0%
15-19 5.4%
All Japan
3-5
ISAAC
19.9%
6-7 13.9% 13.5%
13-14 8.8% 9.6%
16-17 8.3%
All Japan
Elementary school School 
health 
surveillance
6.8%
Junior high school 5.1%
High school 3.6%
trigger wheeze and episodic (viral-induced) wheeze.9
It is important that asthma phenotypes should be re-
flected on the differential diagnosis and therapeutic
strategies.
3. Epidemiology of Childhood Asthma
3.1. Prevalence
Reported prevalence differs depending on the survey
method. Two survey methods, the International
Study of Asthma and Allergies in Childhood (ISAAC)
and the American Thoracic Society-Division of Lung
Diseases (ATS-DLD) with modification are utilized in
Japan.10,11 The prevalence of asthma in Japan as de-
termined by ATS-DLD shows 3.2-6.5%. Asthma preva-
lence in school children has been increasing in these
two decades according to the survey targeting at chil-
dren of the same elementary schools in the same
given area. However, very recent survey data indi-
cates the prevalence tends to be declining (Table 3)
with the following characteristics: (1) it is more com-
Hamasaki Y et al.
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Fig.　3　Mortality from asthma in children from 1980 to 2009.
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mon among juveniles, particularly male children,
more specifically male infants; (2) it varies twofold or
more among regions; (3) it shows higher prevalence
in children with family history of allergic diseases.
Children with higher BMI (>90th percentiles) indicate
higher prevalence of asthma from infancy to adoles-
cence.12
Prevalence of childhood asthma in Japan is ranked
at the middle of various countries in the world.
3.2. Complications
Allergic rhinitis, allergic conjunctivitis, and atopic
dermatitis are common as coexisting allergic dis-
eases caused by the same mechanism as asthma. Of
note, the complication rates of these allergic diseases
are30%.13
3.3. Prognosis
The remission rate is lower in patients with more se-
vere asthma. Remission is defined as an asympto-
matic status without any treatment, and is thus differ-
entiated from cure. A remission status that continues
for 5 years or longer is considered a clinical cure.
Furthermore, if respiratory function and airway
hyper-responsiveness recover to normal levels, the
status is determined as a functional cure.
Sixty percent of children who have had wheezing
before age 6 experience no more wheezing at the age
of 6 years old. On the other hand, 52-72% of children
diagnosed as asthmatic at the age of 6, turn out to
present with asthma symptoms at the age of 22 years
old.14,15
3.4. Death from Asthma (Fig. 3)
The number of deaths from asthma during childhood
has markedly decreased. The following characteris-
tics can be noted:
(1) Mortality in patients with asthma, aged 5-34
years, has decreased to0.1 per 100,000 population;
(2) Mortality in infants and children aged 0-4 years
is higher than that in older children;
(3) Mortality in patients aged 15-19 years de-
creases and is higher among males and unstable;
(4) Suffocation is the leading cause of death;
(5) Most deaths result in patients with severe per-
sistent asthma, but some patients with moderate or
mild persistent asthma may also die from asthma16;
(6) Sudden and unexpected exacerbation and de-
layed appropriate consultation are common as causes
of death from asthma; and
(7) Misjudgment of the severity of exacerbation
and excessive dependence on pressurized metered
dose inhalers (pMDI) of short-acting β2 stimulants
are other causes of death.
To reduce the number of deaths from asthma,
early and accurate diagnosis and treatment, and pa-
tient education should be thoroughly conducted. In-
structions about the appropriate use of pMDI of
short-acting β2 stimulant against acute exacerbation,
thorough anti-inflammatory therapy with inhaled cor-
ticosteroids, and good compliance to asthma manage-
ment, are particularly important.
4. Management of Acute Asthma Exacerba-
tion
4.1. Intensity of Asthma Exacerbation
The intensity of asthma exacerbation is classified into
4 stages: mild, moderate, severe exacerbations, and
respiratory failure. It is based on the degree of im-
pairment of respiratory status and the conditions of
daily life such as eating, speaking, sleeping and exer-
cising (Table 4). Since infants cannot complain of
dyspnea themselves, the intensity of exacerbation in
them is determined on the basis of objective findings.
Childhood Asthma
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Table　4　Intensity of asthma exacerbation
Component Mildexacerbation
Moderate
exacerbation
Severe
exacerbation
Respiratory 
failure
Respiratory status
Wheezing Mild Apparent Marked Reduced oreliminated
Retractive breathing None - mild Apparent Marked Marked
Prolonged expiration (-) (+) Apparent† Marked
Orthopnea Can lie down Prefers sitting position Bends forward
Cyanosis (-) (-) Possibly (+) (+)
Respiratory rate Slightly increased Increased Increased Undetermined
Normal respiratory rate
<2 months <60/min
2-12 months <50/min
1-5 years old <40/min
6-8 years old <30/min
Feeling of dyspnea
During rest (-) (+) Marked Marked
During walking (+) when in ahurry
Marked during 
walking
Difficulty in 
walking Can not walk
Daily life
Speech Pause after onesentence
Pause after 
phrases
Pause after one 
word Impossible
Feeding Almost normal Slightly difficult Difficult Impossible
Sleep Can sleep Occasionally wake up Disturbed Disturbed
Disturbed conscious-
ness
Agitation (-) Slightly excited Excited Confused
Lowered level 
of consciousness (-) (-) Slightly lowered (+)
PEF
(before β2 inhalation) >60% 30-60% <30% Unmeasurable
(after β2 inhalation) >80% 50-80% <50% Unmeasurable
SpO2 (room air) ≥96% 92-95% ≤91% <91%
PaCO2 <41 mmHg <41 mmHg <41-60 mmHg >60 mmHg
†Difficult to determine during tachypnea. During severe exacerbation, the expiratory phase is at least twice longer than the inspiratory 
phase.
There are several criteria. It is not required that all criteria be met.
As intensity of exacerbation increases, infants present with see-saw breathing, not shoulder breathing. During expiration and inspiration,
distention and depression of the chest and abdomen repeat like a seesaw. Exclude intentional abdominal breathing.
Table　5　Symptoms during severe exacerbation in infantile asthma
1. Severe cough (with occasional vomiting)
2. Marked wheezing (occasionally reduced)
3. Depression of suprasternal space and supraclavicular fossa and between ribs
4. Tachypnea
5. Nasal alar breathing
6. Seesaw breathing
7. Comfort when held upright (orthopnea)
 8. Inability to sleep
 9. Cyanosis
10. Moaning
11. Tachycardia
12. Ill-temper
13. Scream
14. Lowered level of consciousness
Ill-temper, vomiting, screaming, and difficulty sleep-
ing unless held by mother are important interview
items for severe exacerbation (Table 5).
The criteria of intensity are determined by oxygen
saturation (SpO2) measured by pulse oximeter and
peak expiratory flow (PEF) by spirometer. However,
since SpO2 widely varies among infants compared
with school children, caution should be taken in
evaluating the intensity of exacerbation in infants.
4.2. History Taking at Outpatient Department
At the outpatient department, the intensity, duration
and cause of exacerbation must be assessed. The pa-
tient’s previous history of exacerbation and medical
Hamasaki Y et al.
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Table　6　Formulas for glucocorticosteroids
Intravenous injection
Initial doses Maintenance doses
2-15 y.o. <2 y.o. 2-15 y.o. <2 y.o.
Hydrocortisone 5-7 mg/kg 5 mg/kg
5-7 mg/kg
every 6 hours
5 mg/kg
every 6-8 hours
Prednisolone 1-1.5 mg/kg 0.5-1.0 mg/kg
0.5 mg/kg
every 6 hours
0.5-1 mg/kg
every 6-12 hours
(max: 2 mg/kg/day)
Methyl-prednisolone 1-1.5 mg/kg 0.5-1.0 mg/kg
1-1.5 mg/kg
every 6 hours
0.5-1.0 mg/kg
every 6-12 hours
Per oral administration
Prednisolone 0.5-1.0 mg/kg/day (divided in three doses)
Alternative: Betamethasone or dexamethasone syrup 0.5 ml (0.05 mg)/kg/day (divided in two doses)
Intravenous injection: infuse for 10-30 min. Pay attention to allergic reaction.
Hydrocortisone: discontinue within 3-4 days.
Systemic administration of glucocorticosteroids should be limited to less than three occasions per month. Patient should be referred to an 
expert in cases requiring more than these.
treatment on such occasions, if any, is also evaluated
before a treatment plan is determined.
4.3. Treatment of Acute Exacerbation in Outpa-
tient Departments (Fig. 4)
Treatment of mild exacerbation: Administer an in-
haled β2 stimulant (salbutamol or procaterol) using a
nebulizer. Either give 0.1-0.3 mL to infants and 0.3-0.5
mL to school children or older adolescents, diluted in
physiological saline (2 ml) or DSCG inhalant solution
(1 ampule = 2 mL). After β2 stimulant inhalation for
15-30 min, when cough and wheezing disappear, and
SpO2 becomes97% and the PEF rates become 80%
of predicted values andor personal best, the patient
can go home. If mild cough and wheezing remain
even after the β2 stimulant inhalation, administer an
inhaled β2 stimulant again 20-30 min later. If the β2
stimulant induces no response or exacerbates symp-
toms, conduct an additional treatment equivalent to
that for moderate exacerbation.
Treatment of moderate exacerbation: Administer
an inhaled β2 stimulant using a nebulizer. Administer
oxygen inhalation on patients with <95% SpO2. For pa-
tients with insufficient response, do the inhalation
again 20-30 min later. Inhalation can be repeated
three times. If ineffective, consider additional treat-
ment. (See below.) When a favorable response is ob-
tained after the initial treatment, the patient should
be observed for an additional hour. If asymptomatic
then, give instructions about future treatment and al-
low the patient to go home. If no remission is
achieved after 2 or more β2 stimulant inhalations,
conduct an additional treatment. In the case of an in-
fant, treat himher after hospitalization.
Additional treatment for moderate exacerbation:
Administer a steroid andor aminophylline. However,
caution should be taken for adverse effects when us-
ing aminophylline. If additional treatment results in
unfavorable response or exacerbates symptoms, treat
the patient after hospitalization.
a) Steroids: Administer a steroid via an intravenous
or oral route. See Table 6 for initial and maintenance
doses. Even on patients with moderate exacerbation,
consider using an intravenous steroid for early medi-
cal treatment if they are patients (1) under treatment
step 3 or above for long-term management; (2) with a
history of hospitalization due to asthma exacerbation
in the past year; or (3) with a history receiving en-
dotracheal intubation for the treatment of asthma ex-
acerbation induced by impaired consciousness.
b) Aminophylline: Indication of aminophylline is
difficult to be secure unequivocally; aminophylline is
not recommended for the patients shown in Table 7.
4.4. Treatment and Procedures in Wards
Indications for in-hospital treatment are shown in Ta-
ble 8. Patients with respiratory failure require inten-
sive care with the assistance of emergency specialists
and anesthesiologists.
Treatment of severe exacerbation: Administer an
inhaled β2 stimulant with a nebulizer along with oxy-
gen inhalation. Start initial transfusion along with in-
travenous steroid administration (Table 6). Amino-
phylline can be administered concomitantly. How-
ever, caution should be taken for patients aged 0-2
years (Table 9). If symptoms are markedly improved,
follow up the patient every 4-6 hours while heshe is
undergoing β2 stimulant inhalation and maintenance
Hamasaki Y et al.
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Table　7　Patients with moderate exacerbation for whom 
aminophylline administration is not advisable (2-15 years old)
1. Patients with a history of convulsions or with complications 
of CNS disease.
2. Caution should be taken in treatment of the following pa-
tients whose serum theophylline levels cannot be quickly 
measured.
(a) Patients with a history of adverse effects caused by 
aminophylline or theophylline.
(b) Patients periodically receiving sustained release the-
ophylline, with serum theophylline level maintained at
>15 microgram/mL.
(c) Patients for whom it is difficult to determine the safety 
of intravenous aminophylline infusion, because of
above, or the use status of theophylline is unclear.
Table　8　Indications for hospital admission
1. Severe exacerbation and respiratory failure
2. Moderate exacerbation
- Past history of severe exacerbation
- Not improved by ambulatory treatment for about 2 hours
- Moderate exacerbation, continuing from the previous day 
and accompanied by sleep disturbance
(Hospitalize patients who are younger than 2 years old)
3. Complications
- Pneumonia, atelectasis, mediastinal emphysema, subcu-
taneous emphysema, pneumothorax, etc.
Table　9　Cautions against aminophylline administration for
patients younger than 2 years old
1. If β2 stimulants or steroids are not effective for severe ex-
acerbation or respiratory failure, theophylline should be
prescribed by a specialist.
2. Do not prescribe theophylline for the patients with convul-
sive disorders, such as febrile convulsions and epilepsy.
3.  If there is fever, carefully refer to indications.
4. Determine dosage based on 10 microgram/mL of serum 
level. Monitor serum level as needed. Adjust dosage as
needed, with an upper limit of 15 maicrogram/mL.
5.  Theophylline clearance is reduced by fever, viral infection, 
foods, concomitant drugs, etc. In some cases, serum lev-
els are elevated.
transfusion. If needed, concomitantly conduct re-
peated glucocorticosteroid administration and con-
tinuous intravenous aminophylline infusion. If exacer-
bation shows no improvement at 30 min after the
start of treatment, proceed with an additional treat-
ment. Consider continuous isoproterenol (e.g.
Asthpul) inhalation.17-19 During this treatment, moni-
tor blood pressure, heart rate, respiratory rate, SpO2,
etc. The continuous inhalation is usually very effec-
tive, whose effects can be noted within 30 min. Peri-
odically conduct intravenous glucocorticoidsteroid
administration (Table 6), which may be discontinued
within several days after remission. (Table 10)
4.5. Treatment of Respiratory Failure
Respiratory failure results in the alleviation and disap-
pearance of wheezing and causes instead severe cya-
nosis, and may be accompanied by urinary and fecal
incontinence and unconsciousness. Analyze arterial
blood gases to assess respiration, and examine the
presence of complications that preclude treatment
(subcutaneous emphysema, mediastinal emphysema,
atelectasis, pneumonia, pneumothorax, and the like).
Although there is no definite indication for artificial
respiratory management, when one or more of the
following signs are apparent, consider it indicated:
(1) Reduced respiratory sounds and wheezing in
the presence of cyanosis;
(2) Impaired consciousness resulting in somno-
lence or coma;
(3) <60 mmHg PaO2 (<90% SpO2) even after suffi-
cient oxygen inhalation;
(4) Elevated PaCO2 (65 mmHg or5 mmHgh).
Usefulness of noninvasive positive ventilation is
still under investigation for childhood asthma.
4.6. Complications with Acute Asthma Exacerba-
tion
Air leak syndrome: Mediastinal emphysema, subcuta-
neous emphysema and pneumothorax are major
forms of air leak syndrome. In pneumothorax, pa-
tients complain of chest pain which exacerbates with
exertion and deep respiration. Cough and dyspnea is
often observed. Leaked air is usually absorbed spon-
taneously.
Atelectasis: In acute asthma exacerbation, airway
obstruction often occurs with airway constriction, mu-
cus hypersecretion and submucosal edema, resulting
in pulmonary atelectasis after air absorption in bron-
chi and alveoli of the lung. Atelectasis is most often
observed in the middle lobe of right lung as a silhou-
ette sign on Chest X-ray. CT-scan is more helpful for
diagnosis. Treatment of asthma exacerbation is the
highest priority, and postural drainage, physical ther-
apy and administration of expectants may be helpful.
5. Basics of Long-Term Management of
Childhood Asthma
5.1. Severity Determination
Asthma severity is classified into 4 levels: intermit-
tent, mild persistent, moderate persistent and severe
persistent, and the level of severe persistent includes
most severe persistent as a sub-group.
The severity of disease in patients not taking long-
term management drugs is shown in Table 11. If
long-term management drugs are already adminis-
tered, determine the “true” severity considering the
present treatment step (Table 12). For example, if the
“apparent” severity of a patient at treatment step 2 is
mild persistent, determine the “true” severity as their
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Table　10　Continuous inhalation therapy with β2 agonist
Nebulizer
Inspiron nebulizer & face mask (or O2 tent)
Inhalation liquid
R/L-isoproterenol (0.5%) 2-5 ml (or L-isoproterenol 10-25 ml) + 0.9%NaCl 500 ml
(double dose of R/L-isoproterenol (0.5%) can be used according to symptoms)
Methods
1. Start with 50%O2 at 10 L/min.
2. Adjust O2 concentration and fl ow in order to maintain SpO2 over 95%.
3. If patient’s status is not improved after 30 min, step up the inhalation condition, or consider management with respirator.
4. When patient’s status is improved, step down the inhalation condition and stop continuous inhalation therapy; then change 
to intermittent inhalation with β2 stimulant.
Monitoring
1. SpO2 with pulse oximeter, ECG, blood pressure, respiratory rate
2. Electrolytes, CPK, LDH, GOT, blood gas
Cautions
1. Keep in mind the timing to change to management with respirator.
2. Regular sputum cough-up, body position change and body movement are encouraged.
3. Watch out for obstruction in tubes and failure of inhalation devices (give special attention to clogging of Inspiron nebulizer).
4. Watch out for signs of myocardial infarction: abnormal ECG fi ndings and chest pain Check cardiac enzymes (CPK GOT 
and LDH), and consider changing to therapy with management with respirator.
Table　11　Defi nition of asthma severity in Japanese Pediatric Guideline
Asthma severity Symptoms
Intermittent
• Seasonal cough and/or wheeze (2-3 times/year)
• Sometimes dyspnea also, but recovers soon with SABA
Mild persistent
• Cough and/or mild wheezing; more than 1/month, less than 1/week
• Sometimes dyspnea also, but it does not continue for long enough to disturb daily life
Moderate persistent
• Cough and/or mild wheezing; more than 1/week, but not everyday
• Sometimes progresses to moderate to severe exacerbation, and disturbs daily life
Severe persistent
• Cough and/or mild wheezing occurs everyday
• Moderate to severe exacerbation occurs 1-2/week, disturbing daily life and sleep
Most severe persistent (sub-group of 
severe persistent)
• Asthma symptoms continue despite the treatment for severe persistent asthma.
• Frequent asthma exacerbation requiring treatment at ER and hospitalization.
Daily life is disturbed to a large extent.
intersection point, i.e. moderate persistent asthma. In
patients with symptoms not controlled by treatment
step 4, whose “apparent” severity is moderate or se-
vere persistent, the “true” severity is determined as
the most severe persistent asthma.
Comparison of asthma severities between children
and adults demonstrates one-level differences: inter-
mittent, mild persistent, and moderate persistent in
adults correspond, respectively, to mild persistent,
moderate persistent, and severe persistent in chil-
dren.
5.2. Treatment Goal of Childhood Asthma
Treatment goal of childhood asthma is shown in Ta-
ble 13. Although the ultimate goal of childhood
asthma treatment is complete remission or cure,
practical targets in daily life are (1) controlling symp-
toms, (2) restoring andor maintaining normal respi-
ratory functions, and (3) keeping good quality of life
(QOL).
5.3. Control Level
Control levels are determined by symptoms, interfer-
ence with daily activities and frequency of inhalation
of short-acting β2 stimulants (Table 14).
5.4. Control of Asthma
The level of complete control is the status which
JPGL 2012 intends to help non-specialist physicians
to aim at in asthma treatment and management. Im-
portant factors in attempts to attain this goal are: (1)
appropriate use of anti-inflammatory drugs, (2) elimi-
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Table　12　How to determine true asthma severity in patients under treatment with anti-asthma drugs
Asthma severity decided from pa-
tient’s symptoms without consid-
ering current treatment step
Current treatment step
Step 1 Step 2 Step 3 Step 4
Intermittent asthma Intermittent asthma Mild persistent Moderate persistent Severe persistent
Mild persistent asthma Mild persistent Moderate persistent Severe persistent Severe persistent
Moderate persistent asthma Moderate persistent Severe persistent Severe persistent Most severe persistent
Severe persistent asthma Severe persistent Severe persistent Severe persistent Most severe persistent
Table　13　Treatment goal of childhood bronchial asthma
Although fi nal goal is remission or cure, the aims of daily 
control are:
1. Complete control of asthma symptoms
Reduced or no need for β2 stimulants in exacerbation.
No symptoms day and night.
2. Normal respiratory functions
Stable PEF rate. Stable pulmonary function tests.
Improved airway hyper-responsiveness (no symptom ag-
gravation after exercise, cold air inhalation, etc.).
3. Improved QOL
Normal daily life, including sports. No absence from 
school.
No side effects associated with drug therapies.
nation of environmental risk factors, and (3) educa-
tional and enlightening activities for patients and
caregivers regarding adequate asthma management
in daily life. The first factor, i.e., appropriate use of
anti-inflammatory drugs, becomes the most efficient
and effective strategy along with the recent develop-
ment of anti-inflammatory drugs for chronic airway
inflammation. Favorable control can be achieved by
selecting an appropriate treatment step based on
asthma severity. However, insufficient treatment, in-
appropriate medication, and unavoidable exacerba-
tion factors result in poor control. The asthma control
test was devised for the evaluation of control levels,
the result of which would help adjust the treatment
and management towards favorable control.
5.5. Evaluation Methods of Asthma Control Lev-
els
(1) Asthma dairy: A diary kept by a patient would
be useful for doctors to gain access to the information
pointing to asthma control through the patient’s own
description of respiratory symptoms, and conditions
of sleeping, feeding, and exercising in daily life. The
information about drug use and the values of peak
flow meter monitoring would also be important for
the evaluation of control. In addition, assessment of
the respiratory functions by spirometer is important.
(2) Childhood Asthma Control Test (C-ACT)20: C-
ACT is a childhood asthma control test used in many
countries for children aged 4-11 years. The test con-
sists of 7 questions, of which diseased children an-
swer the first 4 and their parents answer the remain-
ing 3. The first 4 questions are of a face scale type to
allow children to answer them easily. Scoring is as
follows: 27 points is complete control;20 is favorable
control; and <20 is poor control. Long-term manage-
ment is conducted with a goal of 27 points in the
minds of medical staff. For children aged 12, the
Asthma Control Test (ACT) for adults can be used.
(3) Japanese Pediatric Asthma Control Program
(JPAC)21: Severity and control status can be assessed
by the JPAC system. It allows the selection of treat-
ment step according to the guideline. Step-up and
step-down may also be determined. Scoring is as fol-
lows: 15 points is complete control; 12-14 is favorable
(but still insufficient) control; and11 is poor control.
Conduct treatment and management with a goal of 15
points in mind. Full scores in both C-ACT and JPAC
correspond to well-controlled state in JAGL 2013.
5.6. Avoidance of Exacerbation Factors
Most patients with childhood asthma have atopic dia-
thesis and produce specific IgE antibodies to mites in
house dust. Tests are needed to determine the spe-
cific IgE antibodies to house dust mites and other
possible allergens, and the elimination of these aller-
gens from patients’ living environment is necessary.
5.7. Allergy Tests and Assessment
Mean total IgE values vary with age. High values are
those that exceed the mean +2 SD. The first step of
investigating the allergens of childhood asthma is to
presume environmental antigens by history taking.
Routine examinations include skin tests and measure-
ment of serum specific IgE antibodies in the blood.
However, even if the results prove positive for spe-
cific IgE antibodies, they are not all causes of asthma.
5.8. Instructions for Environmental Improvement
(Table 15)
Cleaning rooms with a vacuum cleaner is an impor-
tant measure against mite antigens. Using a wood or
cushioned floor as flooring material is effective.
Measures for bedclothes are also important; bed-
clothes should preferably be vacuumed at least once
a week. Sensitization to pets (e.g. cats, dogs, and ro-
dents) may induce exacerbation, so contact with
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Table　14　Asthma control levels
Component of control
Classifi cation of asthma control
Well-controlled Partially controlled Poorly controlled
Mild symptoms none
≥1/month
≤1/week
≥1/week
Apparent symptoms none none ≥1/month
Interference with normal activity none none ≥1/month
SABA use for symptom control none
≥1/month
≤1/week
≥1/week
Control levels are evaluated by conditions during the recent 4 weeks.
Mild symptoms indicate transient cough and/or wheezing induced by exercise, laughing and crying. Also included are short periods of 
coughing at the time of awakening and during sleep.
Apparent symptoms indicate continuous coughing and wheezing with dyspnea and chest tightness.
>80% of predicted/personal best in PEF and/or FEV1.0%, <20% of circadian changes in PEF, and <12% of FEV increase by β2 stimulant
inhalation are preferable as well-controlled conditions.
At the time of assessment, hospital admission due to severe exacerbation, use of oral glucocorticosteroid for symptom control, and sea-
sonal exacerbation in recent 12 months should be considered.
Table　15　Points for improvement in environmental conditions
Bedding Use anti-mite sheets and covers; wash bedding frequently and hang it outdoors to dry in the sun
Mattress Do not use mattresses; wooden fl oors are preferable
Sofa Use sofas made of leather or artifi cial leather; no fabric-made sofas
Stuffed toys Do not use stuffed toys; use washable ones if necessary
Furniture Use easily cleanable furniture only
Drapes Use window shades instead of curtains; washable curtains if necessary
Pet animals Do not keep mammals and/or birds inside rooms
Vacuum cleaner Use one equipped with 2-layered dust bag
Potted plants Do not grow plants inside rooms
Laundry Do not hang the laundry inside rooms
Heating appliances Exhaust gas must be ducted outdoors if kerosene or gas heater is used
Materials for building houses Eliminate architectural materials containing volatile chemicals such as aldehyde and phenol
Tobacco-smoking Persuade family members to discontinue smoking inside rooms
these animals should be avoided.
5.9. Instructions for Smoking Cessation
Smoking, active or passive, is an exacerbation factor
of asthma. Smoking by pregnant mothers affects the
respiratory function of their children after birth.22
Parents with smoking habits must be instructed
about the need for smoking cessation as a vital com-
ponent of childhood asthma treatment. If children
themselves are smokers, instruct them about the ad-
verse influences on treatment and have them un-
dergo smoking cessation therapy.
6. Long-Term Management by Medication
6.1. Formulations and Characteristics of Long-
Term Management Drugs (Controllers)
Long-term management drugs (controllers) are those
drugs that are continuously used to reduce and elimi-
nate patients’ asthma symptoms, improve their QOL,
and normalize and maintain their respiratory func-
tion. Controller drugs should have anti-inflammatory
effects. Drugs with anti-inflammatory effects include
inhaled corticosteroids (ICSs), leukotriene receptor
antagonists (LTRAs), and theophylline. Per-oral ster-
oid administration for long-term management is lim-
ited to the most severe cases because of adverse ef-
fects. ICSs are routinely used for patients at the level
of severity that is higher than moderate persistent,
because ICSs have strong anti-inflammatory action
with relatively low systemic adverse effects. Long-
acting β2 agonists (LABAs) are concomitantly used
with an ICS for long-term management; LABAs
should not be used alone.23
(1) Inhaled corticosteroids (ICSs): ICSs potently
suppress airway inflammation and play an important
role in long-term asthma control. As airway inflamma-
tion is ameliorated, there occurs an improvement in
subjective symptoms, respiratory function, and air-
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Table　16　Asthma management in children under 2 years of age
Step 1 Step 2 Step 3 Step 4
Basal
therapy
SABA
As needed
LTRA
and/or
DSCG
ICS
(medium dose)
ICS (high dose)
possibly add
LTRA
Additional
therapy
LTRA
and/or
DSCG
ICS (low dose)
LTRA
LABA
(p.o. or adhesive skin patch)
LABA (p.o. or adhesive skin patch)
Theophylline (maintain at 5-10 mg/mL in blood conc.)
can be considered
LTRA, leukotriene receptor antagonist; ICS, inhaled corticosteroid; DSCG, disodium cromoglycate; LABA, long acting beta agonist.
LABA is discontinued when good control level is achieved. LABA (p.o.) is defi ned as the β2 stimulants prescribed as twice a day.
Theophylline is not used for patients under 6 months of age. Theophylline is not recommended for patients with history of convulsion.
Prescription of theophylline for patients with fever should be with caution.
Strongly recommend that uncontrollable patients with step 3 or step 4 management strategy be referred to experts in treating severe 
childhood asthma.
way hyper-responsiveness, and also hospitalization
due to exacerbation and deaths from asthma de-
crease in number.24-26 However, no evidence has
been obtained regarding improved natural outgrowth
of symptoms by persistent use of ICSs for long peri-
ods.27,28 Combination drugs of ICS and LABA can be
used for children aged 5 years. Select an adequate
drug formulary depending on the patient’s age and
or inhalation techniques to maximize the efficiency of
inhalation.
(2) Leukotriene receptor antagonists (LTRAs):
LTRAs inhibit bronchoconstriction and airway inflam-
mation,29 and are effective for long-term manage-
ment. In many cases, LTRAs improve respiratory
function and reduce the frequency of exacerbations
within 1-2 weeks after administration. In patients with
mild persistent asthma, LTRAs are as effective as
ICSs.30,31 Efficacy of LTRAs as additional drugs to
ICSs has also been demonstrated.32-34
(3) Sustained release theophylline (SRT): SRT,
which has a bronchodilator action and an anti-
inflammatory effect, is used as a controller. The dos-
age of theophylline is determined with factors that in-
fluence metabolisms, such as individual differences,
infections, meal contents, and concomitant drugs.
Caution should be taken for an elevated serum theo-
phylline level resulting from decreased clearance
caused by fever during viral infection. In infants, an
intractable convulsion associated with theophylline
administration causes a problem.35
(4) Long-acting β2 agonists (LABAs): Since β2
stimulants have no inhibitory effect on airway inflam-
mation, LABAs may be used concomitantly with ICSs
or other anti-inflammatory drugs. Besides inhaled LA-
BAs, transdermal patches36,37 and per-oral medicines
are available as LABAs in Japan. The serum tu-
lobuterol level is maintained for 24 hours after past-
ing of transdermal tulobuterol patch.
6.2. Long-Term Management Plan
Selection of treatment step based on asthma severity:
In a pharmacotherapy plan for long-term control of
asthma, determine its severity on the basis of symp-
toms and their frequency during the most recent one
month (see Table 11) and select a long-term manage-
ment drug combination for the treatment step deter-
mined by the severity (Table 12). The pharmacother-
apy plan for long-term management is divided into
three age groups: <2, 2-5, and 6-15 years old (Table
16-18). Table 19 indicates doses of different products
of ICS in treatment steps 1 to 4.
During treatment, the control status can be evalu-
ated by monitoring subtle asthma symptoms, appar-
ent asthma exacerbation, daily life restrictions such
as in sleeping, feeding and speaking, and frequency
of unexpected inhalations of β2 stimulant (Table 14).
Favorable control is indicated by 20% diurnal vari-
ation in PEF rate or 80% of the patient’s personal
best rate. Using a control questionnaire, C-ACT and
or JPAC and asthma diary is also useful for the evalu-
ation. Table 20 lists criteria that indicate the status of
favorable asthma control.
If control is insufficient or poor, try to achieve com-
plete control through additional treatment or step-up.
It is also important to re-examine the appropriateness
of medication, allergen avoidance and the effects of
psychosocial factors. If there are no positive effects
even at treatment step 4, consider hospitalization for
further treatment38 or per-oral corticosteroid admini-
stration as in the case of most severe persistent
asthma.
If complete control has been achieved for 3 months
or longer, consider a step-down depending on the se-
verity, history of disease, respiratory function, and
medication. Provided a step-down is applicable, re-
duce the dosage to the lowest recommended dose to
maintain the control level. When management works
out well and asthma symptoms are controlled below
the intermittent level, and, at the same time, respira-
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Table　17　Asthma management in children 2-5 years of age
Step 1 Step 2 Step 3 Step 4
Basal
therapy SABA as needed
LTRA
and/or
DSCG
and/or
ICS (low dose)
ICS
(medium dose)
ICS (high dose)
+ (possibly add one or more of the following drugs)
LTRA
Theophylline
LABA or SFC
Additional
therapy
LTRA
and/or
DSCG
LTRA
LABA
or SFC
Theophylline
(consider)
Consider the following:
Increase ICS/SFC to higher doses
or
p.o. steroid
LTRA, leukotriene receptor antagonist; ICS, inhaled corticosteroid; DSCG, disodium cromoglycate; LABA, long-acting beta agonist; SFC, 
salmeterol/fl uticazone combined drug.
LABA is discontinued when good control level is achieved. When SFC is started, oral and percutaneous LABA should be discontinued.
Addition of SFC to ICS is acceptable; however, total dose of steroid is limited within the dose of basal therapy. SFC should be used for
patients 5 years or more of age.
Uncontrollable patients with step 3-management strategy are recommended to be referred to experts in treating severe childhood asthma.
As an additional therapy at step 4, an increase of ICS/SFC to higher doses or p.o. steroid therapy or long-term admission management is
considered. Patients should be controlled under experts in treating severe childhood asthma.
Table　18　Asthma management in children 6-15 years of age
Step 1 Step 2 Step 3 Step 4
Basal
therapy SABA as needed
ICS (low dose)
and/or
LTRA
and/or
DSCG
ICS
(medium dose)
ICS (high dose)
+ (possibly add one or more of the following drugs)
LTRA
Theophylline
LABA or SFC
Additional
therapy
LTRA
and/or
DSCG
Theophylline
(consider)
LTRA
Theophylline
LABA
or SFC
Consider the following:
Increase ICS/SFC to higher doses
or
p.o. steroid
LTRA, leukotriene receptor antagonist; ICS, inhaled corticosteroid; DSCG, disodium cromoglycate; LABA, long-acting beta agonist; SFC, 
salmeterol/fl uticazone combined drug.
LABA is discontinued when good control level is achieved. When SFC is started, oral and percutaneous LABA should be discontinued. 
Addition of SFC to ICS is acceptable; however, total steroid dose is limited within the dose of basal therapy.
It is recommended that uncontrollable patients with step 3 management strategy be referred to experts in treating severe childhood asth-
ma.
As an additional therapy at step 4, an increase of ICS/SFC to higher doses or p.o. steroid therapy or long-term admission management is
considered. Patients should be controlled under experts in treating severe childhood asthma.
tory function is favorable after reduction to the lowest
recommended dosage, treatment can be discontinued
(Fig. 5). At present, there are no explicit criteria for
discontinuation of drugs. Even if symptoms are not
apparent any longer (i.e. a status without treatment or
symptoms), the patient should be followed up. That is
because remission does not mean cure.
7. Diagnosis and Treatment of Persistent
Cough
7.1. Persistent Cough and Asthma
No definite criteria exist for persistent cough in chil-
dren. In adults, The Japanese Respiratory Society de-
fines three types of coughs: chronic cough, pro-
longed cough and acute cough. Symptoms continue,
respectively, for 8 weeks, <8 weeks 3 weeks, and
<3 weeks. Patients with underlying diseases which
cause persistent cough for over 8 weeks are diag-
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Table　19　Dose comparison of ICS
Manufacture of drug Low dose (mcg)/day Medium dose (mcg)/day High dose† (mcg)/day
Fluticasone (FP) -100 -200 -400
Beclomethasone (BDP) -100 -200 -400
Ciclesonide (CIC) -100 -200 -400
Budesonide (BDP-DPI) -200 -400 -800
Budesonide inhalation solution (BIS) -250 -500 -1,000
†High doses of ICS should preferably be administered under the control of a physician with enough experience in childhood asthma man-
agement.
Table　20　Conditions for well-controlled status
1. No wheeze or exacerbation; no limitation in daily life (e.g. sleeping, exercising).
2. No subtle respiratory symptoms indicative of airway hyper-responsiveness (i.e. transient wheeze and cough associated with 
exercise, laughing and/or URI).
3. No needs for β2 stimulant. No improvement of FEV1 by β2 stimulant inhalation.
4. Full scores of JPAC and/or C-ACT.
5. Daily variation of PEF <20%. Keeping of FEV1 >80% of self best.
6. FEV1 is kept >80% of expected value; rise in FEV1 by β2 stimulant inhalation <12%.
Caution: No overmedication! Always remind yourself.
nosed as having chronic cough in a broad sense. In
this broad sense, asthma is the leading cause of
chronic cough. Other causes are postnasal drainage,
diseases associated with other atopic illness, and
gastro-esophageal reflux.
Cough-variant asthma is a unique condition demon-
strating persistent cough which has airway hyper-
responsiveness but no history of wheezing. Inhalation
of β2 stimulant is effective as its treatment. Some of
the patients with cough-variant asthma end up by hav-
ing bronchial asthma.
Underlying mechanisms of persistent cough are
(1) airway inflammation by infection and allergy, (2)
direct andor indirect stimulation by sputum, nasal
discharge and gastric juice, and (3) stimulation by air-
way smooth muscle constriction and mucosal edema
in various pathological conditions.
7.2. Treatment of Persistent Cough
Fundamental strategy for the treatment of persistent
cough is first to determine the underlying mecha-
nisms, and then deal with them. In the cases of poor
asthma control, step up the treatment level, eliminate
exacerbation factors from the patient’s immediate en-
vironment and educate himher about asthma con-
trol.
8. Inhalers and Spacer
Inhalation therapy is critical and effective for the daily
management and treatment of asthma exacerbation
in children including infants. Have a good under-
standing of the characteristics (i.e. merits and demer-
its) of inhalers for the selection of an adequate type
based on the child’s status.
8.1. Inhalers
Inhalers are classified into nebulizers and metered
dose inhalers. Three types of nebulizers, based on
their drive systems, are available: jet, ultrasonic, and
mesh. Metered dose inhalers include the pressurized
metered dose inhaler (pMDI) and the dry powder in-
haler (DPI). In Table 21, combinations of nebulizers
and aiding tools (i.e. mask and spacer) and drugs for
different age groups are demonstrated. It can be se-
lected by assessing various conditions such as effi-
ciency of inhalation, compliance, patients’ preference,
financial matters, and so forth.
(1) Nebulizer: Since respiratory control is not re-
quired during inhalation, a nebulizer can be used re-
gardless of age, if a mask is used. Jet nebulizers are
most widely used for inhalation therapy of asthma.
Mesh nebulizers are a subtype of ultrasonic nebuliz-
ers. Mesh nebulizers are lightweight, power saving,
and have high vaporizing capacity. Ordinary ultra-
sonic nebulizers are unsuitable for inhaling anti-
asthma drugs because of thermal denaturation and
concentration changes of drugs in the reserve-tank. A
defect of ultrasonic nebulizer is that they do not nebu-
lize suspensions of budesonide inhalation solution
very well.39
(2) Use of nebulizers: Children should inhale at a
resting respiratory rate in a sitting position. Those old
enough to breathe orally inhale with a mouthpiece,
attached to the nozzle of nebulizer, put in the mouth.
With infants, use a nebulizer with a mask attached to
the nozzle, to cover the mouth and nose. Adhesion of
mask to patient’s face greatly influences inhalation ef-
ficiency, which gets reduced by nasal inhalation or
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Fig.　5　Strategy of long-term management of asthma. 
†At the assessment of patient asthma control, it is important to check drug-adherence, inhalation tech-
niques, and environmental controls for eliminating aggravating factors.
‡Keep treatment regimen at least 3 months till patient’s control levels are well maintained.
§It is preferable to step up treatment regimen when patient’s control levels stay at the partially controlled 
level for 3 months.
¶In cases where patient’s control level is expected to improve through education (†), treatment regimen 
can be maintained at the same step.
Diagnosis
Decision on treatment-step
Assessment of asthma control†
Maintain
Patient education¶
Reconsider
diagnosis
Partially
controlled
Well
controlled
Step down
Stop add-on drugs, decrease
anti-inflammatory treatment
Poorly
controlled
Step up
Increase anti-inflammatory treatment
Use add-on drugs
Re-assessment of asthma control†
Give attention
to over-doses
Check
aggravating
factors
Keep well controlled 
level for certain period 
to be stabilized‡
Under treatment§
Table　21　Combination of inhalation device and aiding tools
Age Drug Inhalation devices and aiding tools
Baby
Solution nebulizer + mask
pMDI spacer with mask
Infant
Solution nebulizer + mask or mouth piece
pMDI spacer with mask or mouth piece
School
children
Solution nebulizer + mouth piece
pMDI spacer with mouth piece
DPI (-)
crying.40,41
(3) Metered dose inhalers: pMDI and DPI are
available. If no spacer is used for pMDI, synchronize
spray and inhalation. Even in infants, for whom spray
and inhalation cannot be synchronized, pMDI can be
employed by using a spacer and a mask. Using DPI, a
patient inhales a drug through self-respiration. School
children or older adolescents can use DPI because a
certain amount of inspiratory force is required and a
spacer and a mask cannot be applied.
8.2. Spacer
A spacer is an indispensable aiding instrument (tool)
for pMDI in infants who cannot accurately perform
the procedures for the synchronization of spray and
inhalation. Concomitant use of a spacer allows inhala-
tion at a normal respiratory rhythm even without syn-
chronizing spray and inhalation; it thus results in in-
creased inhalation efficiency. In addition, a spacer is
useful in adsorbing large particles (5 μm) onto the
inner wall of the spacer to prevent deposition of ex-
cess agent in the oral cavity and reduce adverse ef-
fects. In infants who cannot breathe through the
mouth, cover the nose and mouth with a mask to
maintain inhalation efficiency.
Many types of spacers are available. Select a spacer
with data assuring aerodynamic properties, clinical
usefulness and safety. The effectiveness of a spacer is
greatly influenced by concomitant agents, procedures
as well as its shape, structure, and physical proper-
ties. To maximize the benefit from a spacer, mask the
face closely without leakage and prevent static elec-
tricity.
Technical mastery in the adequate use of inhala-
tion devices and aiding accessories is essential to ob-
tain maximal efficacy of inhalation drugs (Table 22).
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Table　22　Check list of inhalation therapy
• Nebulizer
 bite mouth-piece fi rmly
 expectorate salivary fl uid without reversing from time to 
time
 can ventilate through mouth
 adhere mask tightly on the face
 can ventilate without crying
 wipe away solution on the face after inhalation
• pMDI
 can synchronize actuation and inhalation
 can ventilate through mouth
 can ventilate slow and deep
 can hold breath for certain periods of time
• pMDI + spacer
 when using mouth-piece, can bite mouth-piece fi rmly
 when using mask, can adhere mask tightly on the face
 inhale at every actuation
 can ventilate without crying
 can hold breath for certain periods of time
• DPI
 keep device in appropriate position
 do not blow away drug-powder before inhalation
 can ventilate with strong inspiration
 can ventilate deep
 can hold breath for certain periods of time
• Other points
 gargle or drink water after inhalation (in the case of us-
ing ICS)
9. Patient Education
To perform asthma treatment effectively, educate pa-
tients and their caregivers to be actively involved in
the treatment.42,43
(1) Infants (2-4 years old): Do not discomfort pa-
tients during treatment. Get them interested in the
treatment and kept motivated. Encourage and compli-
ment them on their good performance in inhalation
and habituate them to the treatment gradually.
(2) School-age children (from 5 years old to lower
grades of elementary school): Explain the patho-
physiology of asthma to patients, using simple terms
and metaphors, to make them understand the need
for treatment. Instruct patients about the way of
breathing with abdominal muscles, PEF measure-
ment, and other matters cheerfully as if they were
playing some kind of game.
(3) Pre-puberty children (upper graders of elemen-
tary school): Instruct patients about the need for con-
tinuing treatment without interruption. According to
their level of understanding, educate them about the
pathophysiology of asthma and its treatment. Since it
is difficult to make such young patients take charge
of the part of treatment and management that their
parents have taken care of, compliment them on their
efforts to achieve self-fulfillment and eventual self-
management.
(4) Children in puberty (junior high school stu-
dents or older): More patients likely disobey their
parents because of parent-child conflicts during pu-
berty. Treatment and management will be inter-
rupted by insufficient education and instruction. This
results in poor control and increased risks of death
from asthma. Directly instruct patients at consulta-
tion. It is often the case that not enough time may be
taken in outpatient departments, so it is far more ef-
fective to hospitalize patients with severe persistent
asthma for education and instruction during a sum-
mer vacation, or when they can take time off from
schoolwork without difficulty.
9.1. Improvement in Adherence
Sharing a treatment goal and establishing a partner-
ship are important to both patient and doctor. Repeat-
edly check the patient’s basic knowledge and skills at
consultation to help himher take a positive attitude
toward treatment and high adherence.44
9.2. Pubertal to Adolescent Asthma
Problems increase during puberty, e.g., low compli-
ance, remodeling, and death from asthma.45 Under-
standing the characteristics and problems of pubertal
asthma on the patient’s part is important for treat-
ment and management (Fig. 6). Points of manage-
ment and treatment for pubertal asthma are demon-
strated in Table 23.
10. Exercise-Induced Asthma (EIA)
(1) EIA: EIA is a phenomenon in which wheezing
and dyspnea occur temporarily during exercise. Its
pathology is yet to be clarified. Cooling in the airway,
caused by hyperventilation during exercise,46 and ele-
vated osmolarity in the airway epithelium, caused by
water loss, are potential underlying pathophysiol-
ogy.47,48 Increased airway temperature after exercise
may also be involved.49
(2) Diagnosis: If coughing, wheezing, and dyspnea
occur during or after exercise, a diagnosis of EIA
may be made. Conduct an exercise stress test to
quantitate EIA.50,51 If maximal percent falls of FEV1
and PEF are, respectively, larger than 15% and 20%, a
diagnosis of EIA is confirmed.
(3) Severity: The maximum decreasing rate of
FEV1 after exercise is higher in patients with more
severe asthma. This serves as a parameter in the de-
termination of the severity of asthma.52 Since EIA is
also associated with airway hyperresponsiveness, his-
tory taking about EIA serves as a clue to whether or
not the current treatment step is appropriate.
(4) Prevention: To prevent EIA, select the appropri-
ate treatment step based on the severity. If in fact EIA
has occurred, prevent its repetition by resorting to
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Fig.　6　Problems of adolescent asthma.
Factors of “Under treatment”
    Patients and families
        Low adherence
        Lack of self-management
            misjudgment of severity
            no adequate treatment at acute exacerbation
        Change of life-style
        School, Work
        Psychogenic problems
    Hospitals
        Lack of education and enlightenment
        No adequate management
        Unsuitable transfer to internist
    School and workplace
        No care for asthma
        Lack of support
    Society
        Medical expense
        Limited medical offer (time, facility)
Increase of aggravating factors
    Allergen exposure (mites, pet animals)
    Tobacco-smoking, alcohol
    Psychogenic factors
Pathophysiology
    Remodeling
    Airway inflammation
    Complications
      (sinusitis, nasopharyngitis)
    Menstruation, obesity
    Steroid resistance
Frequent exacerbation, severe intractable asthma, asthma death
the procedures shown in Table 24.
(5) Exercise instructions: Do not restrict exercise
because it otherwise benefits the child’s growth in
various ways. Parents, teachers, school officials,
school physicians, and attending physicians should
collaborate to take measures so that children with
asthma can safely participate in exercise at pre-
schools and schools.
11. Participation in Events at Preschools
and Schools
Parents of children with asthma and their attending
physicians should help to make supportive plans for
their extracurricular studies and club activities, such
as school trips, school camps, and excursions in co-
operation with preschools and schools so that those
children can participate in those events whenever
possible. Instruct children with asthma and their par-
ents beforehand about cautions they should keep in
mind when taking part in such events and measures
against acute exacerbation.
(1) If children with asthma develop acute exacerba-
tion while participating in an event, make them inhale
a bronchodilator (β2 stimulant) earlier than in a regu-
lar treatment schedule because of the special situ-
ation. Likewise, depending on the status of daily
symptoms, consider an increase of daily dose of ICS
andor short-term per-oral administration of a corti-
costeroid.
(2) Hand a disease referral form to a physician in
emergency so that the patient can receive appropriate
treatment at a nearby medical institution in acute ex-
acerbation that occurs during travel.
(3) If patients have histories of allergic symptoms
after contact with animals, caution should be taken
for contact with animals at zoos and similar facilities.
(4) Stand on the windward side to avoid wafts of
smoke from fireworks or a campfire.
(5) Instruct roommates, if applicable, to refrain
from wrestling and pillow fights on beds to keep the
room free from allergens and stimulants.
11.1. Precautions for School Activities
(1) Since EIA is most likely to occur during a dead
run or a long-distance race, instruct patients to start
slowly.
(2) If allergies occur upon a child’s contact with an
animal, then keep the child from taking care of ani-
mals at school.
(3) Have class teachers explain about EIA to pa-
tient’s classmates.
(4) Take care so as for a child with asthma to avoid
allergens and airway stimulators during clean up du-
ties at school.
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Table　23　Countermeasures for adolescent asthma
1. Recognition of features and pathophysiology in adolescent 
asthma
2. Evaluation
Adherence
Disincentive factors
Motivation to adherence
Ease of access to medical facilities
Control levels
Asthma diary
PEF (peak expiratory fl ow) monitoring
EIA
JPAC (Japanese Pediatric Asthma Control Program)
C-ACT (Childhood Asthma Control Test)
Remodeling, small airway obstruction and airway infl am-
mation
Circadian variation of PEF
Flow volume curve
3. Support for increasing self management ability
Establishment of good relationships between medical 
staff and patients and family members
Easy and sufficient explanation for asthma pathophysi-
ology
Provision of education programs
Sufficient advice for cessation of smoking, school activi-
ties, work, marriage, child birth, etc.
Raise awareness of asthma-death
Provision of specifi c action plan for asthma manage-
ment
Reconfi rmation of own management and treatment goal
4. Establishment of medical support in various places
Local community
Preparation of instruction forms in acute exacerbation
Provision of medical information about patients
School
Use of instruction table for school life management in
school
Preparation of referral forms in school trips, extra curric-
ular activities and travels
Workplace
Support to enhance understanding in workplace
5. Assessment of complications
Allergic rhinitis, sinusitis,
Pneumothorax, subcutaneous emphysema, mediastinal
emphysema
Psychosomatic diseases
6. Reevaluation of treatment and management
Evaluation of current medical plan
Step up therapeutic plan if necessary
Table　24　Prophylaxis of exercise-induced asthma (EIA)
1. Warm-ups before exercise†
2. Drugs
β2 stimulant‡
DSCG§
LTRA¶
Other medications‖
3. Others
Mask＃
Training regularly††
†Light exercise causing mild EIA reduces EIA that is induced 
subsequent to hard exercise because of the refractory period.
‡Inhalation or intake of β2 stimulant 15 min or 60 min before ex-
ercise inhibits EIA. However, use of β2 stimulant should be limited,
because β2 stimulant may induce airway hyper-responsiveness. 
Reduction of EIA by training regularly is preferable.
§Inhalation of DSCG 15 min before exercise prevents reduction 
of FEV1 and PEF.
¶LTRA inhibits EIA.
‖EIA indicates poor control of asthma. Adequate treatment with 
controller drugs including ICS and LTRA prevents EIA.
＃Wearing mask prevents EIA because it helps inhalation of air
with adequate moisture and temperature.
††Regular training reduces severity of EIA.
11.2. Instruction Table for School Life Manage-
ment
An instruction table (http:www.gakkohoken.jp.bo
okbo0002.html, in Japanese) for school life manage-
ment was made for allergic diseases, which include
asthma, atopic dermatitis, allergic conjunctivitis, ana-
phylaxis and food allergies, and allergic rhinitis. In Ja-
pan, children with these 5 allergic diseases are asked
to submit this table to preschool and school admini-
strations; the table gives the information about the
treatment for the child patients’ allergic diseases, in-
cluding asthma, with precautionary measures to take
on the part of the administration. The table also gives
emergency contact telephone numbers, and names of
consulting medical institutions and physicians in
emergency for patients’ safety.
11.3. Precautions for Vaccination
Conditions such as bronchial asthma, atopic dermati-
tis, allergic rhinitis, urticaria, or allergic predisposi-
tion alone do not preclude vaccination. However, cau-
tion should be taken as to whether patients are poten-
tially allergic to vaccine components. Conduct a pre-
liminary diagnosis considering previous allergic
symptoms and vaccine additives. ICS and topical use
of glucocorticosteroid does not exclude vaccination.
11.4. Vaccine Additives and Inoculum Compo-
nents for Allergy
Reportedly, gelatin (stabilizer), thimerosal (antisep-
tics), egg ingredients (culture components), and an-
timicrobials can cause allergy. The physician should
carefully refer to the attached document before giv-
ing an injection because constituents may differ in
formulation produced in different pharmaceutical
companies.
Childhood Asthma
Allergology International Vol 63, No3, 2014 www.jsaweb.jp 353
Fig.　7　Diagnostic approach for severely retarded children with bronchial asthma.
†If the origin of wheezing cannot be determined, start work-up from upper airway.
Suction, relaxation of muscles
Judge the origin (upper or lower airway)†
Cervical X-ray, CT-scan,
Laryngoscopy
Blood exam
Chest X-ray, CT-scan
Bronchoscopy
β2 stimulant
inhalation
Treat according
to the illness 
Cervical X-ray, CT-scan, Laryngoscopy
Stridor/wheezing
No improvement
Inspiratory wheezing (upper airway)
Negative findingsPositive findings
No improvement Improvement
Re-assessment of
other illnesses Asthma
No improvement Improvement
Expiratory wheezing (lower airway)
11.5. Major Vaccines for Children with Asthma
(1) Influenza vaccine: Influenza vaccines can be
safely used to inoculate children, who eat egg-
processed products without serious adverse effects.
(2) Mixed vaccine for measles and rubella (MR): If
immediate hypersensitivity reaction (e.g. urticaria)
occurs immediately after the first inoculation with an
MR vaccine, then measure the titer of measles anti-
body (neutralizing or EIA-IgG antibody) and avoid a
second inoculation if antibody is found, or perform an
intradermal reaction test before a second inoculation
is given. Avoid the second inoculation into patients
with an immediate anaphylactic reaction after the first
inoculation with an MR vaccine.
11.6. Considerations for Surgical Operation
Since asthma is a risk factor in putting the patient un-
der general anesthesia, especially inhalation anesthe-
sia, caution should be taken in the management of
physical conditions before and during surgical opera-
tion and also for respiratory management after opera-
tion.
For non-emergency surgery, a period exceeding at
least 2 weeks of no paroxysmal symptoms is required
after exacerbation even in patients with mild persis-
tent asthma. If asthma exacerbation occurs within 2
weeks of the previous exacerbation, surgical opera-
tion should be postponed. In the cases of non-
emergency operation, no-exacerbation periods of 2 or
3 months before operation is recommended, because
it takes several months before airway hyper-
responsiveness becomes sufficiently reduced.
Complications and allergic reactions to drugs,
medical materials, latex, foods, and the like must be
investigated prior to surgery. Caution is demanded
for patients under systemic steroid administration for
6 months or longer and also for those with adrenocor-
tical insufficiency. Systemic steroid administration
should be applied after surgical operation as well.
12. Cautions for Severely Retarded Chil-
dren with Bronchial Asthma
12.1. Diagnosis
Making a diagnosis of bronchial asthma in child pa-
tients with severe retardation is not easy, because
these patients often have stridor andor wheezing
due to underlying pathophysiological conditions
other than bronchial asthma. Difficulty of conducting
respiratory function tests in severely retarded chil-
dren makes it more difficult to make a definite diag-
nosis.
12.2. Differential Diagnosis
Basic treatment for stridor andor wheezing (i.e. suc-
tion of secretion, airway management, postural
change, relaxation of body muscles) is the first step
in making a diagnosis of bronchial asthma. If wheez-
ing does not change by these procedures, further as-
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sessment of diagnosis is advanced through the chart
shown in Figure 7. Chest X-ray, CT-scan, laryngo-
scopy and bronchoscopy may be useful. Improve-
ment of stridor andor wheezing by inhalation of β2
stimulants may indicate a higher possibility of bron-
chial asthma. However, unequivocal diagnosis cannot
be made by this procedure, because the expectant ef-
fect by hydration may improve wheezing.
12.3. Treatment and Management
Basic strategy in the treatment and management for
severely retarded children with bronchial asthma is
the same as asthma children without severe retarda-
tion. However, specific consideration is needed for
the treatment and management for the severely re-
tarded when they are in acute exacerbation as well as
for a long-term management of them with controller
drugs.
12.4. Caution in Acute Exacerbation
Intensity of exacerbation is assessed based on objec-
tive signs and symptoms (i.e. wheezing, cough, re-
tractive respiration, etc.), which should be compared
with those of the patient under usual conditions. Spe-
cial devices must be applied to the patient with airway
management for inhalation therapy. Application of
per-oral theophylline and intravenous injection of
aminophylline has to be careful. That is because
many severely retarded children are associated with
convulsive illnesses. As children with severe retarda-
tion easily fall into respiratory failure, early and inten-
sive treatment is necessary.
12.5. Long-Term Management
As shown previously, asthma diagnosis is difficult to
make in severely retarded children. Long-term man-
agement with anti-asthma drugs should not continue
without regular evaluation of drug efficacy. Differen-
tial diagnosis is necessary in the cases without im-
provement by treatment based on asthma severity
ranks. When ICS is applied, adequate combinations
of inhalation devises, accessories and drugs (i.e. jet
nebulizer + mask + budesonide inhalation solution)
must be selected. Frequent use of β2 stimulant must
be considered with a combined use of anti-
inflammatory drugs such as ICS.
Regular clearance of airways by suction, postural
change and other kinds of physical therapy are im-
portant in the long-term management of asthma in se-
verely retarded children with bronchial asthma.
13. Conclusion
A new edition of JAGL has been introduced, which re-
flects recent progresses of strategy in asthma treat-
ment and management for children. A long-term
management with anti-inflammatory controller drugs,
elimination of airborne antigens from the patient’s liv-
ing environment, and enlightenment and education
about bronchial asthma including pathophysiology
are the three fundamental factors for the treatment
and management of childhood asthma. It is important
to maintain “a well-controlled state” for long enough a
period, which in turn affords good quality of life and
may ultimately result in remission and cure. “Well-
controlled state” is defined as completely controlled
status without subtle symptoms such as even a short
period of wheezing. Essential information is summa-
rized in this review.
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